China Unveiling GlaxoSmithKline Bribery Investigation Details On 14th of May

    China Unveiling GlaxoSmithKline Bribery Investigation Details

China Unveiling GlaxoSmithKline Bribery Investigation DetailsReuters

Chinese authorities will unveil the latest developments related to their GlaxoSmithKline investigation after the Ministry of Public Security accused Asia-based executives at Britain’s largest drugmaker of bribery.

According to a Ministry of Public Security statement, China’s authorities will reveal to the media at on 14 May their findings after a probe into GSK following allegations that unnamed executives routed 3bn yuan ($488m, £307m, €365m) in bribes to doctors through 700 travel agencies and consultancies over six years.

In July 2013, Chinese police arrested four GSK executives in connection with the bribery allegations.

On 30 April, GSK said: “The People’s Republic of China (PRC), acting through various government agencies, continues its investigation into alleged crimes and violations of law by GSK’s China operations.

“The Group takes these allegations seriously and is continuing to cooperate fully with the Chinese authorities in this investigation. The Group has informed the US Department of Justice, the US Securities and Exchange Commission and the UK Serious Fraud Office (SFO) regarding the investigation and is co-operating fully with these agencies.

“It is not possible at this time to make a reliable estimate of the financial effect, if any, that could result from these matters.”

GSK has also admitted that some Chinese executives appeared to have broken the law, but CEO Andrew Witty said the head office had no prior knowledge about the wrongdoing.


One comment

  1. dbunker

    It appears team GSK is experiencing yet another of those sticky data wickets with a heart drug.

    “But even bypassing strokes failed to move the drug over the goal line on efficacy compared to a placebo.”

    “After the first Phase III failure, lead investigator Harvey White looked over the data and told Reuters, “I’m convinced there is a signal here of efficacy.”

    “”We will now work to further analyse the data and better understand the findings,” says Patrick Vallance, GSK’s president of pharmaceuticals R&D.”

    Oh well, given time, I’m sure their Ethics Dept. will figure out how to saturate the market with it anyway.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: